The effects of electrical stimulation exercise on muscles injected with botulinum toxin type-A (botox)

Journal of Biomechanics

Volumn 46, Issue 1, 2013, Pages 36-42

  Fortuna, Rafael ^a   Horisberger, Monika ^b   Vaz, Marco Aurélio ^c   Van der Marel, Robert ^a   Herzog, Walter ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Botox; Botulinum toxin; Electrical stimulation; Muscle atrophy; Muscle spasticity; Muscle weakness; NZW rabbits; Skeletal muscle

Indexed keywords

BOTOX; BOTULINUM TOXINS; ELECTRICAL STIMULATIONS; MUSCLE ATROPHY; MUSCLE WEAKNESS; NZW RABBITS; SKELETAL MUSCLE; SPASTICITY;

STRENGTH OF MATERIALS;

MUSCLE;

BOTULINUM TOXIN A; GLYCOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPLETION; ELECTROSTIMULATION THERAPY; EXTENSOR MUSCLE; FEMALE; FEMORAL NERVE; KNEE EXTENSOR TORQUE; MUSCLE ATROPHY; MUSCLE CONTRACTION; MUSCLE EXERCISE; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULOSKELETAL SYSTEM PARAMETERS; NERVE STIMULATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTECTION; QUADRICEPS FEMORIS MUSCLE; RABBIT; THERAPY EFFECT; TREATMENT DURATION;

ANIMALS; BOTULINUM TOXINS, TYPE A; ELECTRIC STIMULATION THERAPY; FEMALE; FEMORAL NERVE; INJECTIONS, INTRAMUSCULAR; MUSCLE CONTRACTION; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; RABBITS;

EID: 84871418423     PISSN: 00219290     EISSN: 18732380     Source Type: Journal    
DOI: 10.1016/j.jbiomech.2012.09.025     Document Type: Article

References (61)

1. Albavera-Hernandez C., Rodriguez J.M., Idrovo A.J. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clinical Rehabilitation 2009, 23:394-407.
2. Ansved T., Odergren T., Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology 1997, 48:1440-1442.
3. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. Journal of Neuroscience 2008, 28:3689-3696.
4. Ascher B., Talarico S., Cassuto D., Escobar S., Hexsel D., Jaen P., Monheit G.D., Rzany B., Viel M. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)-Part I: upper facial wrinkles. Journal of the European Academy of Dermatology and Venereology: JEADV 2010, 24:1278-1284.
5. Baker R., Jasinski M., Maciag-Tymecka I., Michalowska-Mrozek J., Bonikowski M., Carr L., MacLean J., Lin J.P., Lynch B., Theologis T., Wendorff J., Eunson P., Cosgrove A. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Developmental Medicine and Child Neurology 2002, 44:666-675.
6. Bakheit A.M., Pittock S., Moore A.P., Wurker M., Otto S., Erbguth F., Coxon L. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 2001, 8:559-565.
7. Bakheit A.M., Ward C.D., McLellan D.L. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. Journal of Neurology, Neurosurgery, and Psychiatry 1997, 62:198.
8. Bayram S., Sivrioglu K., Karli N., Ozcan O. Low-dose botulinum toxin with short-term electrical stimulation in poststroke spastic drop foot: a preliminary study. American Journal of Physical Medicine & Rehabilitation/ Association of Academic Physiatrists 2006, 85:75-81.
9. Black J.D., Dolly J.O. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. The Journal of Cell Biology 1986, 103:535-544.
10. Borodic G.E., Ferrante R., Pearce L.B., Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Movement Disorders: Official Journal of the Movement Disorder Society 1994, 9:31-39.
11. Borodic G.E., Joseph M., Fay L., Cozzolino D., Ferrante R.J. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head & Neck 1990, 12:392-399.
12. Brashear A., Gordon M.F., Elovic E., Kassicieh V.D., Marciniak C., Do M., Lee C.H., Jenkins S., Turkel C., Botox Post-Stroke Spasticity Study Group Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. The New England Journal of Medicine 2002, 347:395-400.
13. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle & Nerve. Supplement 1997, 6:S146-S168.
14. Cardoso E., Rodrigues B., Lucena R., Oliveira I.R., Pedreira G., Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arquivos De Neuro-Psiquiatria 2005, 63:30-33.
15. Carroll T.J., Herbert R.D., Munn J., Lee M., Gandevia S.C. Contralateral effects of unilateral strength training: evidence and possible mechanisms. Journal of Applied Physiology 2006, 101:1514-1522.
16. Cosgrove A.P., Graham H.K. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Developmental Medicine and Child Neurology 1994, 36:379-385.
17. Cote T.R., Mohan A.K., Polder J.A., Walton M.K., Braun M.M. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. Journal of the American Academy of Dermatology 2005, 53:407-415.
18. Dodick D.W. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache 2003, 43(Suppl 1):S25-S33.
19. Fortuna R., Vaz M.A., Youssef A.R., Longino D., Herzog W. Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox). Journal of Biomechanics 2011, 44:39-44.
20. Frasson E., Priori A., Ruzzante B., Didone G., Bertolasi L. Nerve stimulation boosts botulinum toxin action in spasticity. Movement Disorders: Official Journal of the Movement Disorder Society 2005, 20:624-629.
21. Garner C.G., Straube A., Witt T.N., Gasser T., Oertel W.H. Time course of distant effects of local injections of botulinum toxin. Movement Disorders: Official Journal of the Movement Disorder Society 1993, 8:33-37.
22. Goldstein E.M. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. Journal of Child Neurology 2006, 21:189-192.
23. Graham H.K., Aoki K.R., Autti-Rämö I., Boyd R.N., Delgado M.R., Gaebler-Spira D.J., Gormley M.E., Guyer B.M., Heinen F., Holton A.F., Matthews D., Molenaers G., Motta F., García Ruiz P.J., Wissel J. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait & Posture 2000, 11:67-79.
24. Habermann E. 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn-Schmiedeberg's Archives of Pharmacology 1974, 281:47-56.
25. Herzog W., Leonard T.R. Force enhancement following stretching of skeletal muscle: a new mechanism. Journal of Experimental Biology 2002, 205:1275-1283.
26. Herzog W., Leonard T.R. Depression of cat soleus-forces following isokinetic shortening. Journal of Biomechanics 1997, 30:865-872.
27. Hesse S., Brandl-Hesse B., Seidel U., Doll B., Gregoric M. Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A. Restorative Neurology and Neuroscience 2000, 17:1-8.
28. Hesse S., Jahnke M.T., Luecke D., Mauritz K.H. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neuroscience Letters 1995, 201:37-40.
29. Hesse S., Lucke D., Malezic M., Bertelt C., Friedrich H., Gregoric M., Mauritz K.H. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. Journal of Neurology, Neurosurgery, and Psychiatry 1994, 57:1321-1324.
30. Hesse S., Reiter F., Konrad M., Jahnke M.T. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clinical Rehabilitation 1998, 12:381-388.
31. Hortobagyi T., Maffiuletti N.A. Neural adaptations to electrical stimulation strength training. European Journal of Applied Physiology 2011, 111:2439-2449.
32. Hughes R., Whaler B.C. Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparation by Cl. botulinum type A toxin. The Journal of Physiology 1962, 160:221-233.
33. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Movement Disorders: Official Journal of the Movement Disorder Society 2004, 19(Suppl 8):S109-S115.
34. Kang B.S., Bang M.S., Jung S.H. Effects of botulinum toxin A therapy with electrical stimulation on spastic calf muscles in children with cerebral palsy. American Journal of Physical Medicine & Rehabilitation/ Association of Academic Physiatrists 2007, 86:901-906.
35. Koman L.A., Mooney J.F., Smith B., Goodman A., Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. Journal of Pediatric Orthopedics 1993, 13:489-495.
36. Koman L.A., Brashear A., Rosenfeld S., Chambers H., Russman B., Rang M., Root L., Ferrari E., Garcia de Yebenes Prous J., Smith B.P., Turkel C., Walcott J.M., Molloy P.T. Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001, 108:1062-1071.
37. Kuehn B.M. FDA requires black box warnings on labeling for botulinum toxin products. JAMA: The Journal of the American Medical Association 2009, 301:2316.
38. Lange D.J., Brin M.F., Warner C.L., Fahn S., Lovelace R.E. Distant effects of local injection of botulinum toxin. Muscle & Nerve 1987, 10:552-555.
39. Lange D.J., Rubin M., Greene P.E., Kang U.J., Moskowitz C.B., Brin M.F., Lovelace R.E., Fahn S. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle & Nerve 1991, 14:672-675.
40. Longino D., Butterfield T.A., Herzog W. Frequency and length-dependent effects of Botulinum toxin-induced muscle weakness. Journal of Biomechanics 2005, 38:609-613.
41. Longino D., Frank C., Herzog W. Acute botulinum toxin-induced muscle weakness in the anterior cruciate ligament-deficient rabbit. Journal of Orthopaedic Research 2005, 23:1404-1410.
42. Longino D., Frank C., Leonard T.R., Vaz M.A., Herzog W. Proposed model of botulinum toxin-induced muscle weakness in the rabbit. Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society 2005, 23:1411-1418.
43. Lukban M.B., Rosales R.L., Dressler D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. Journal of Neural Transmission (Vienna, Austria: 1996) 2009, 116:319-331.
44. Maffiuletti N.A. Physiological and methodological considerations for the use of neuromuscular electrical stimulation. European Journal of Applied Physiology 2010, 110:223-234.
45. Minamoto V.B., Hulst J.B., Lim M., Peace W.J., Bremner S.N., Ward S.R., Lieber R.L. Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation. Developmental Medicine and Child Neurology 2007, 49:907-914.
46. Molenaers G., Schörkhuber V., Fagard K., Van Campenhout A., De Cat J., Pauwels P., Ortibus E., De Cock P., Desloovere K. Long-term use of botulinum toxin type A in children with cerebral palsy: Treatment consistency. European Journal of Paediatric Neurology 2009, 13:421-429.
47. Naidu K., Smith K., Sheedy M., Adair B., Yu X., Graham H.K. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Developmental Medicine and Child Neurology 2010, 52:139-144.
48. Polak F., Morton R., Ward C., Wallace W.A., Doderlein L., Siebel A. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Developmental Medicine and Child Neurology 2002, 44:551-555.
49. Restani L., Antonucci F., Gianfranceschi L., Rossi C., Rossetto O., Caleo M. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). The Journal of Neuroscience 2011, 31:15650-15659.
50. Russman B.S., Tilton A., Gormley M.E. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle & Nerve 1997, Supplement 6:S181-S193.
51. Sanders D.B., Massey E.W., Buckley E.G. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology 1986, 36:545-547.
52. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980, 87:1044-1049.
53. Seifart A., Unger M., Burger M. Functional electrical stimulation to lower limb muscles after botox in children with cerebral palsy. Pediatric Physical Therapy: The Official Publication of the Section on Pediatrics of the American Physical Therapy Association 2010, 22:199-206.
54. Shaari C.M., George E., Wu B.L., Biller H.F., Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. The Laryngoscope 1991, 101:960-964.
55. Shaari C.M., Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle & Nerve 1993, 16:964-969.
56. Stackhouse S.K., Binder-Macleod S.A., Stackhouse C.A., McCarthy J.J., Prosser L.A., Lee S.C. Neuromuscular electrical stimulation versus volitional isometric strength training in children with spastic diplegic cerebral palsy: a preliminary study. Neurorehabilitation and Neural Repair 2007, 21:475-485.
57. Szabo E. ACL Transection and Electrical Stimulation Training of the Quadriceps in the Rabbit: effects on Strength and Osteoarthritis 2008, University of Calgary, Canada.
58. Ubhi T., Bhakta B.B., Ives H.L., Allgar V., Roussounis S.H. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Archives of Disease in Childhood 2000, 83:481-487.
59. Varghese-Kroll E., Elovic E.P. Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. American Journal of Physical Medicine & Rehabilitation/ Association of Academic Physiatrists 2009, 88:495-499.
60. Wiegand H., Erdmann G., Wellhoner H.H. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn-Schmiedeberg's Archives of Pharmacology 1976, 292:161-165.
61. Yaraskavitch M., Leonard T., Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. Journal of Biomechanics 2008, 41:897-902.